RYALTRIS
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RYALTRIS (RYALTRIS).
RYALTRIS is a fixed-dose combination of olopatadine, a histamine H1-receptor antagonist, and mometasone furoate, a corticosteroid. Olopatadine inhibits histamine release from mast cells and reduces allergic response. Mometasone furoate acts via glucocorticoid receptor agonism, suppressing inflammatory mediators.
| Metabolism | Olopatadine: Not extensively metabolized; primarily excreted unchanged in urine. Mometasone furoate: Undergoes extensive hepatic metabolism via CYP3A4 to multiple metabolites. |
| Excretion | Ryaris (olopatadine/mometasone) undergoes primarily renal excretion; olopatadine is mainly excreted unchanged in urine (≈60-70%) with minor biliary/fecal elimination (<20%). Mometasone furoate is extensively metabolized and its metabolites are excreted equally via bile/feces (≈74%) and urine (≈26%). |
| Half-life | Olopatadine terminal half-life is 8-12 hours; mometasone furoate terminal half-life is approximately 5.8 hours following inhalation. The overall systemic exposure is low due to intranasal administration. |
| Protein binding | Olopatadine is approximately 55% bound to human serum albumin. Mometasone furoate is 98-99% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Olopatadine Vd is 6.0 L/kg after intravenous administration, indicating extensive tissue distribution. Mometasone furoate Vd is 4.5 L/kg, also suggesting wide distribution. |
| Bioavailability | Intranasal olopatadine has a systemic bioavailability of ≈40% (range 30-45%). Intranasal mometasone furoate has negligible systemic bioavailability (<0.1% due to first-pass metabolism and low absorption). |
| Onset of Action | Olopatadine onset of action is within 30 minutes for nasal allergy symptoms. Mometasone furoate onset of action is 12-24 hours for nasal congestion, with full effect over several days. |
| Duration of Action | Olopatadine duration of action lasts 8-12 hours, supporting twice-daily dosing. Mometasone furoate duration is >24 hours, allowing once-daily dosing. Combination product provides 12-hour relief of nasal allergy symptoms. |
1 spray (50 mcg olopatadine / 50 mcg mometasone furoate) per nostril twice daily. Each spray delivers 50 mcg olopatadine and 50 mcg mometasone furoate. Do not exceed 2 sprays per nostril per day.
| Dosage form | SPRAY, METERED |
| Renal impairment | No formal dose adjustment recommended for renal impairment. Use with caution in severe renal impairment (eGFR <30 mL/min/1.73 m²) due to limited data. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); use caution. |
| Pediatric use | Approved for children ≥12 years: 1 spray per nostril twice daily. Not approved for children <12 years; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment needed. Use same dose as adults; monitor for adverse effects (e.g., epistaxis, nasal irritation) due to potential increased sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for RYALTRIS (RYALTRIS).
| Breastfeeding | No data exist on presence of olopatadine or mometasone furoate in human milk, effects on breastfed infant, or milk production. Mometasone furoate is excreted in milk of lactating rats. M/P ratio unknown. Caution advised; consider developmental and health benefits of breastfeeding along with mother's clinical need for RYALTRIS and potential adverse effects on infant. |
| Teratogenic Risk | RYALTRIS (olopatadine hydrochloride and mometasone furoate) is classified as Pregnancy Category C. No adequate and well-controlled studies exist in pregnant women. In animal studies, intranasal mometasone furoate caused decreased fetal weight, umbilical hernia, and delayed ossification at doses ≥ 2 times the maximum recommended human intranasal dose (MRHDID) on a mg/m² basis; olopatadine hydrochloride was not teratogenic in rats and rabbits at doses ≤ 100 times the MRHDID (mg/m²). Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to any ingredient in the formulation."]
| Precautions | ["Nasal discomfort (e.g., epistaxis, ulceration, candidiasis): Monitor for signs of nasal mucosal damage. Discontinue if persistent irritation or infection occurs.","Hypothalamic-pituitary-adrenal axis suppression when used at higher than recommended doses or with prolonged use. Use caution in patients with active or quiescent tuberculosis, untreated fungal/bacterial/systemic viral infections, or ocular herpes simplex.","Potential for growth suppression in children when used long-term due to corticosteroid component.","Avoid use in patients with recent nasal septal ulcers, nasal surgery, or nasal trauma until healing has occurred."] |
Loading safety data…
| Fetal Monitoring | Standard prenatal care; monitor for signs of fetal growth restriction if high doses of corticosteroids are used systemically; no specific fetal monitoring required for intranasal administration. |
| Fertility Effects | Olopatadine: No impairment of fertility in rats at oral doses up to 200 mg/kg (approximately 100 times MRHDID on mg/m² basis). Mometasone furoate: No impairment of fertility in rats at subcutaneous doses up to 15 μg/kg (approximately 0.2 times MRHDID on mg/m² basis). No human data. |